Sponsors (18)
Introduced January 31, 2025 by Chris Pappas · Last progress January 31, 2025
The bill aims to target large-scale fentanyl trafficking, speed scientific review and potential medical access, and provide some retroactive relief — but it also creates broad class-scheduling authority and new sentencing thresholds that raise legal uncertainty, research burdens, and risks of expanded incarceration and public‑health tradeoffs.
Law enforcement and prosecutors get clearer gram-based thresholds and charging guidance so felony penalties focus on large-volume fentanyl traffickers rather than smaller distributors.
Patients with chronic pain and clinicians may gain access to certain fentanyl-related drugs if HHS-supported rescheduling leads to Schedule III classification, enabling medical prescription and supervised use.
Researchers and research institutions can start and run federally sponsored Schedule I studies faster and with fewer administrative barriers (expedited notices, single/multi‑site registrations, limited on‑site manufacturing, and confidentiality protections).
People (especially low-income and racial minority communities) who possess or distribute amounts at or above the new gram thresholds face higher mandatory-minimum exposure and increased incarceration, raising prison populations and taxpayer correction costs.
Broad, class‑style scheduling and structural language create legal uncertainty that can criminalize trace amounts (including lab contamination) and unintentionally capture research compounds, burdening researchers, labs, manufacturers, and small businesses.
Narrowing which analogues are covered in practice and tying coverage to scheduling or HHS determinations could create enforcement gaps that traffickers exploit, and stricter scheduling may divert resources from treatment and prevention to prosecutions, undermining public‑health efforts to reduce overdoses.
Based on analysis of 9 sections of legislative text.
Creates a Schedule I class for broadly defined fentanyl‑related substances, adjusts fentanyl/analogue sentencing thresholds, sets HHS rescheduling rules, adds a research registration pathway, and orders GAO review.
Creates a permanent, class‑wide Schedule I listing for any chemical that fits a broad statutory definition of “fentanyl‑related substance,” while carving out procedures for scientific review and possible removal or rescheduling. It also adjusts quantity thresholds that trigger enhanced federal penalties for fentanyl and certain analogues, creates a special registration pathway to facilitate some Schedule I research, permits limited resentencing or sentence reductions when substances are later rescheduled, requires the Attorney General to issue implementing rules, and directs a GAO study of the policy’s effects within four years.